North America Adalimumab Market - Industry Trends and Forecast to 2027

Lowest Prices Guaranteed Length Publisher Published Date SKU
from $3,500 80 Pages Data Bridge Market Research November, 2020 DAABD16439440
Lowest Prices Guaranteed
Price from $3,500
Length 80 Pages
Publisher Data Bridge Market Research
Published Date November, 2020
SKU DAABD16439440

North America Adalimumab Market - Industry Trends and Forecast to 2027

North America adalimumab market is projected to register a CAGR of 4.9% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
North America Adalimumab Market By Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others), Type (Biologics, Biosimilars), Dosage Strength (40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, Others), Drug Type (Branded, Generics), Route of Administration (Parenteral, Oral), Population Type (Adults, Children), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Tenders, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of North America adalimumab market are:

• Introduction to biosimilar
• Exploration of emerging markets

Market Players:

The key market players for North America adalimumab market are listed below:

• AbbVie Inc.
• CELLTRION INC.
• Biogen
• Coherus BioSciences
• Innovent Biologics, Inc.
• Mylan N.V.
• Zydus Cadila
• Hetero Biopharma Ltd.
• Pfizer Inc.
• Boehringer Ingelheim International GmbH

The single user license is non-downloadable and non-printable. Global Site license allows these actions.


1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of North America Adalimumab Market
1.4 Limitations
1.5 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Currency And Pricing
2.5 Dbmr Tripod Data Validation Model
2.6 Multivariate Modelling
2.7 Indication Lifeline Curve
2.8 Primary Interviews With Key Opinion Leaders
2.9 Dbmr Market Position Grid
2.10 Vendor Share Analysis
2.11 Secondary Sources
2.12 Assumptions
3 Executive Summary
3.1 Pipeline Analysis
4 Regulatory Framework Of North America Adalimumab Market
5 Epidemiology
6 Adalimumab Prescription
7 North America Adalimumab Market: Reimbursement Scenario
7.1 Reimbursement Scenario In The U.S.
7.2 Reimbursement Scenario In China
7.3 Reimbursement Scenario In Japan
7.4 Reimbursement In Central And Eastern Europe
7.5 Reimbursement Scenario In Denmark
7.6 Reimbursement Scenario In Ireland
8 Impact Of Biosimilar
9 Market Overview
9.1 Drivers
9.1.1 Rise In The Prevalence Of Rheumatoid Arhtritis
9.1.2 Increasing Geriatric Population
9.1.3 Increasing Number Of Contract Research Organizations
9.1.4 Introduction To Biosimilars
9.1.5 Exploration Of Emerging Markets
9.2 Restraints
9.2.1 High Costs Of Drugs
9.2.2 Side Effects Of Drugs
9.2.3 Cancer Causing Drugs
9.3 Opportunities
9.3.1 Presence Of Product Pipeline
9.3.2 Strategic Initiatives By Market Players
9.3.3 Increasing Healthcare Expenditure
9.3.4 Presence Of Reimbursement Policies
9.4 Challenges
9.4.1 Loss Of Patents
9.4.2 Availability Of Alternatives
9.4.3 Long Approval Procedure
10 Covid-19 Impact On Adalimumab In Healthcare Industry
10.1 Overview
10.2 Adalimumab And Covid-
10.3 Price Impact Of Covid-
10.4 Impact On Demand
10.5 Impact On Supply Chain
10.6 Strategic Decisions For Manufacturers
10.7 Conclusion
11 North America Adalimumab Market, By Indication
11.1 Overview
11.2 Rheumatoid Arthritis
11.3 Ankylosing Spondylitis
11.4 Chronic Plaque Psoriasis
11.5 Crohn’s Disease
11.6 Ulcerative Colitis
11.7 Psoriatic Arthritis
11.8 Juvenile Idiopathic Arthritis
11.9 Hidradenitis Suppurativa
11.10 Non-infectious Intermediate
11.11 Others
12 North America Adalimumab Market, By Type
12.1 Overview
12.2 Biologics
12.3 Biosimilars
12.3.1 Adalimumab-atto
12.3.2 Adalimumab-bwwd
12.3.3 Adalimumab-adbm
12.3.4 Adalimumab-adaz
12.3.5 Adalimumab-fkjp
12.3.6 Adalimumab-afzb
12.3.7 Others
13 North America Adalimumab Market, By Dosage Strength
13.1 Overview
13.2mg/0.4ml
13.3mg/0.8ml
13.4mg/0.4ml
13.5mg/0.1ml
13.6 Others
14 North America Adalimumab Market, By Drug Type
14.1 Overview
14.2 Branded
14.3 Generics
14.3.1 Amjevita
14.3.2 Hyrimoz
14.3.3 Hulio
14.3.4 Others
15 North America Adalimumab Market, By Route Of Administration
15.1 Overview
15.2 Parenteral
15.3 Oral
16 North America Adalimumab Market, By Population Type
16.1 Overview
16.2 Adults
16.3 Children
17 North America Adalimumab Market, By End User
17.1 Overview
17.2 Hospitals
17.3 Specialty Clinics
17.4 Home Healthcare
17.5 Others
18 North America Adalimumab Market, By Distribution Channel
18.1 Overview
18.2 Hospital Pharmacies
18.3 Retail Pharmacies
18.4 Online Pharmacies
18.5 Direct Tender
18.6 Others
19 North America Adalimumab Market, By Geography
19.1 North America
19.1.1 U.S.
19.1.2 Canada
19.1.3 Mexico
20 North America Adalimumab Market: Company Landscape
20.1 Company Share Analysis: North America
21 Swot
22 Company Profiles
22.1 Abbvie Inc.
22.1.1 Company Snapshot
22.1.2 Revenue Analysis
22.1.3 Company Share Analysis
22.1.4 Product Portfolio
22.1.5 Recent Developments
22.2 Amgen (Europe) Gmbh (A Subsidiary Of Amgen Inc.)
22.2.1 Company Snapshot
22.2.2 Revenue Analysis
22.2.3 Company Share Analysis
22.2.4 Product Portfolio
22.2.5 Recent Developments
22.3 Biogen
22.3.1 Company Snapshot
22.3.2 Revenue Analysis
22.3.3 Product Portfolio
22.3.4 Recent Developments
22.4 Sandoz International Gmbh {A Subsidiary Of Sandoz (A Division Of Novartis Ag)}
22.4.1 Company Snapshot
22.4.2 Revenue Analysis
22.4.3 Product Portfolio
22.4.4 Recent Developments
22.5 Mylan N.V.
22.5.1 Company Snapshot
22.5.2 Revenue Analysis
22.5.3 Product Portfolio
22.5.4 Recent Developments
22.6 Boehringer Ingelheim International Gmbh
22.6.1 Company Snapshot
22.6.2 Revenue Analysis
22.6.3 Product Portfolio
22.6.4 Recent Developments
22.7 Celltrion Inc.
22.7.1 Company Snapshot
22.7.2 Revenue Analysis
22.7.3 Product Portfolio
22.7.4 Recent Developments
22.8 Coherus Biosciences
22.8.1 Company Snapshot
22.8.2 Product Portfolio
22.8.3 Recent Developments
22.9 Fresenius Kabi Deutschland Gmbh (A Subsidiary Of Fresenius Kabi Ag)
22.9.1 Company Snapshot
22.9.2 Revenue Analysis
22.9.3 Product Portfolio
22.9.4 Recent Developments
22.10 Hetero Biopharma Ltd.
22.10.1 Company Snapshot
22.10.2 Product Portfolio
22.10.3 Recent Developments
22.11 Innovent Biologics, Inc.
22.11.1 Company Snapshot
22.11.2 Revenue Analysis
22.11.3 Product Portfolio
22.11.4 Recent Developments
22.12 Pfizer Inc.
22.12.1 Company Snapshot
22.12.2 Revenue Analysis
22.12.3 Product Portfolio
22.12.4 Recent Developments
22.13 Reliance Life Sciences (A Subsidiary Of Reliance Industries Limited)
22.13.1 Company Snapshot
22.13.2 Revenue Analysis
22.13.3 Product Portfolio
22.13.4 Recent Developments
22.14 Samsung Bioepis (A Subsidiary Of Samsung Biologics)
22.14.1 Company Snapshot
22.14.2 Revenue Analysis
22.14.3 Product Portfolio
22.14.4 Recent Developments
22.15 Zydus Cadila
22.15.1 Company Snapshot
22.15.2 Revenue Analysis
22.15.3 Product Portfolio
22.15.4 Recent Development
23 Questionnaire
24 Related Reports
List Of Tables
Table 1 North America Adalimumab Market, Pipeline Analysis
Table 2 Biosimilar Of Adalimumab Launched In The U.S.
Table 3 Prevalence And Incidence Rates Of Ra Worldwide (Case Per 100 Inhabitants)
Table 4 Biologic Drugs Subjected To Patent Loss
Table 5 Alternative Drugs For Inflammatory Diseases Treatment
Table 6 North America Adalimumab Market, By Indication 2019-2027 (Usd Million)
Table 7 North America Rheumatoid Arthritis In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 8 North America Ankylosing Spondylitis In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 9 North America Chronic Plaque Psoriasis In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 10 North America Crohn’s Disease In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 11 North America Ulcerative Colitis In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 12 North America Psoriatic Arthritis In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 13 North America Juvenile Idiopathic Arthritis In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 14 North America Hidradenitis Suppurativa In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 15 North America Noninfectious Intermediate In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 16 North America Others In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 17 North America Adalimumab Market, By Type 2019-2027 (Usd Million)
Table 18 North America Biologics In Adalimumab Market, By Type 2019-2027 (Usd Million)
Table 19 North America Biosimilars In Adalimumab Market, By Type 2019-2027 (Usd Million)
Table 20 North America Biosimilars In Adalimumab Market, By Type 2019-2027 (Usd Million)
Table 21 North America Adalimumab Market, By Dosage Strenght, 2019-2027 (Usd Million)
Table 22 North America 40mg/0.4ml In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 23 North America 80mg/0.8ml In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 24 North America 20mg/0.4ml In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 25 North America 10mg/0.1ml In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 26 North America Others In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 27 North America Adalimumab Market, By Drug Type, 2019-2027 (Usd Million)
Table 28 North America Branded In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 29 North America Generics In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 30 North America Generics Adalimumab Market, By Drug Type, 2018-2027 (Usd Million)
Table 31 North America Adalimumab Market, By Route Of Administration 2019-2027 (Usd Million)
Table 32 North America Parenteral In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 33 North America Adalimumab Market, By Population Type, 2019-2027 (Usd Million)
Table 34 North America Adults In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 35 North America Children In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 36 North America Adalimumab Market, By End User, 2019-2027 (Usd Million)
Table 37 North America Hospitals In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 38 North America Specialty Clinics In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 39 North America Home Healthcare In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 40 North America Others In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 41 North America Adalimumab Market, By Distribution Channel, 2019-2027 (Usd Million)
Table 42 North America Hospital Pharmacies In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 43 North America Retail Pharmacies In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 44 North America Online Pharmacies In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 45 North America Direct Tender In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 46 North America Others In Adalimumab Market, By Region, 2017-2027 (Usd Million)
Table 47 North America Adalimumab Market, By Country, 2018-2027 (Usd Million)
Table 48 North America Adalimumab Market, By Indication, 2018-2027 (Usd Million)
Table 49 North America Adalimumab Market, By Type, 2018-2027 (Usd Million)
Table 50 North America Biosimilars Of Adalimumab Market, By Type, 2018-2027 (Usd Million)
Table 51 North America Adalimumab Market, By Dosage Strength, 2018-2027 (Usd Million)
Table 52 North America Adalimumab Market, By Drug Type, 2018-2027 (Usd Million)
Table 53 North America Generics In Adalimumab Market, By Drug Type, 2018-2027 (Usd Million)
Table 54 North America Adalimumab Market, By Route Of Administration, 2018-2027 (Usd Million)
Table 55 North America Adalimumab Market, By Population Type, 2018-2027 (Usd Million)
Table 56 North America Adalimumab Market, By End User, 2018-2027 (Usd Million)
Table 57 North America Adalimumab Market, By Distribution Channel, 2018-2027 (Usd Million)
Table 58 U.S. Adalimumab Market, By Indication, 2018-2027 (Usd Million)
Table 59 U.S. Adalimumab Market, By Type, 2018-2027 (Usd Million)
Table 60 U.S. Biosimilars Of Adalimumab Market, By Type, 2018-2027 (Usd Million)
Table 61 U.S. Adalimumab Market, By Dosage Strength, 2018-2027 (Usd Million)
Table 62 U.S. Adalimumab Market, By Drug Type, 2018-2027 (Usd Million)
Table 63 U.S. Generics In Adalimumab Market, By Drug Type, 2018-2027 (Usd Million)
Table 64 U.S. Adalimumab Market, By Route Of Administration, 2018-2027 (Usd Million)
Table 65 U.S. Adalimumab Market, By Population Type, 2018-2027 (Usd Million)
Table 66 U.S. Adalimumab Market, By End User, 2018-2027 (Usd Million)
Table 67 U.S. Adalimumab Market, By Distribution Channel, 2018-2027 (Usd Million)
Table 68 Canada Adalimumab Market, By Indication, 2018-2027 (Usd Million)
Table 69 Canada Adalimumab Market, By Type, 2018-2027 (Usd Million)
Table 70 Canada Biosimilars Of Adalimumab Market, By Type, 2018-2027 (Usd Million)
Table 71 Canada Adalimumab Market, By Dosage Strength, 2018-2027 (Usd Million)
Table 72 Canada Adalimumab Market, By Drug Type, 2018-2027 (Usd Million)
Table 73 Canada Generics In Adalimumab Market, By Drug Type, 2018-2027 (Usd Million)
Table 74 Canada Adalimumab Market, By Route Of Administration, 2018-2027 (Usd Million)
Table 75 Canada Adalimumab Market, By Population Type, 2018-2027 (Usd Million)
Table 76 Canada Adalimumab Market, By End User, 2018-2027 (Usd Million)
Table 77 Canada Adalimumab Market, By Distribution Channel, 2018-2027 (Usd Million)
Table 78 Mexico Adalimumab Market, By Indication, 2018-2027 (Usd Million)
Table 79 Mexico Adalimumab Market, By Type, 2018-2027 (Usd Million)
Table 80 Mexico Biosimilars Of Adalimumab Market, By Type, 2018-2027 (Usd Million)
Table 81 Mexico Adalimumab Market, By Dosage Strength, 2018-2027 (Usd Million)
Table 82 Mexico Adalimumab Market, By Drug Type, 2018-2027 (Usd Million)
Table 83 Mexico Generics In Adalimumab Market, By Drug Type, 2018-2027 (Usd Million)
Table 84 Mexico Adalimumab Market, By Route Of Administration, 2018-2027 (Usd Million)
Table 85 Mexico Adalimumab Market, By Population Type, 2018-2027 (Usd Million)
Table 86 Mexico Adalimumab Market, By End User, 2018-2027 (Usd Million)
Table 87 Mexico Adalimumab Market, By Distribution Channel, 2018-2027 (Usd Million)
List Of Figures
Figure 1 North America Adalimumab Market: Segmentation
Figure 2 North America Adalimumab Market: Data Triangulation
Figure 3 North America Adalimumab Market: Droc Analysis
Figure 4 North America Adalimumab Market: North America Vs Regional Market Analysis
Figure 5 North America Adalimumab Market: Company Research Analysis
Figure 6 North America Adalimumab Market: Multivariate Modelling
Figure 7 North America Adalimumab Market: Interview Demographics
Figure 8 North America Adalimumab Market: Dbmr Market Position Grid
Figure 9 North America Adalimumab Market: Vendor Share Analysis
Figure 10 North America Is Expected To Dominate And Asia-pacific Is The Highest Growing Region In North America Adalimumab Market In The Forecast Period Of 2020 To
Figure 11 Rise In The Prevalence Of Rheumatoid Arthritis And Increasing Geriatric Population Is Driving The North America Adalimumab Market In The Forecast Period Of 2020 To
Figure 12 Rheumatoid Arthritis Is Expected To Account For The Largest Share Of The North America Adalimumab Market In 2020 &
Figure 13 North America Is The Fastest Growing Market In North America Adalimumab Market In The Forecast Period Of 2020 To
Figure 14 Drivers, Restraints, Opportunities And Challenges Of North America Adalimumab Market
Figure 15 Market Growth In Clinical Cro (In Usd Millions)
Figure 16 Function Of Cro
Figure 17 Healthcare Expenditure In 2016 And
Figure 18 North America Adalimumab Market: By Indication,
Figure 19 North America Adalimumab Market: By Indication, 2019-2027 (Usd Million)
Figure 20 North America Adalimumab Market: By Indication, Cagr (2020-2027)
Figure 21 North America Adalimumab Market: By Indication, Lifeline Curve
Figure 22 North America Adalimumab Market: By Type,
Figure 23 North America Adalimumab Market: By Type 2019-2027 (Usd Million)
Figure 24 North America Adalimumab Market: By Type, Cagr (2020-2027)
Figure 25 North America Adalimumab Market: By Type, Lifeline Curve
Figure 26 North America Adalimumab Market: By Dosage Strength,
Figure 27 North America Adalimumab Market: By Dosage Strength 2019-2027 (Usd Million)
Figure 28 North America Adalimumab Market: By Dosage Strength, Cagr (2020-2027)
Figure 29 North America Adalimumab Market: By Dosage Strength, Lifeline Curve
Figure 30 North America Adalimumab Market: By Drug Type,
Figure 31 North America Adalimumab Market: By Drug Type , 2019-2027 (Usd Million)
Figure 32 North America Adalimumab Market: By Drug Type, Cagr (2020-2027)
Figure 33 North America Adalimumab Market: By Drug Type, Lifeline Curve
Figure 34 North America Adalimumab Market: By Route Of Administration,
Figure 35 North America Adalimumab Market: By Route Of Administration, 2019-2027 (Usd Million)
Figure 36 North America Adalimumab Market: By Route Of Administration, Cagr (2020-2027)
Figure 37 North America Adalimumab Market: By Route Of Administration, Lifeline Curve
Figure 38 North America Adalimumab Market: By Population Type,
Figure 39 North America Adalimumab Market: By Population Type, 2019-2027 (Usd Million)
Figure 40 North America Adalimumab Market: By Population Type, Cagr (2020-2027)
Figure 41 North America Adalimumab Market: By Population Type, Lifeline Curve
Figure 42 North America Adalimumab Market: By End User,
Figure 43 North America Adalimumab Market: By End User, 2019-2027 (Usd Million)
Figure 44 North America Adalimumab Market: By End User, Cagr (2020-2027)
Figure 45 North America Adalimumab Market: By End User, Lifeline Curve
Figure 46 North America Adalimumab Market: By Distribution Channel,
Figure 47 North America Adalimumab Market: By Distribution Channel, 2019-2027 (Usd Million)
Figure 48 North America Adalimumab Market: By Distribution Channel, Cagr (2020-2027)
Figure 49 North America Adalimumab Market: By Distribution Channel, Lifeline Curve
Figure 50 North America Adalimumab Market: Snapshot (2019)
Figure 51 North America Adalimumab Market: By Country (2019)
Figure 52 North America Adalimumab Market: By Country (2020 & 2027)
Figure 53 North America Adalimumab Market: By Country (2019 & 2027)
Figure 54 North America Adalimumab Market: By Population Type (2020-2027)
Figure 55 North America Adalimumab Market: Company Share 2019 (%)

$3,500
$4,200
 
Research assistance
US: 800.298.5699
Int'l: +1.240.747.3093
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks